Literature DB >> 18525453

Effects of N-3 fatty acids on hepatic triglyceride content in humans.

Gloria Lena Vega1, Manisha Chandalia, Lidia S Szczepaniak, Scott M Grundy.   

Abstract

BACKGROUND: Because dietary N-3 fatty acids reduce plasma triglycerides, they may also decrease hepatic triglyceride content. If so, N-3 fatty acids might constitute a therapy for fatty liver.
METHODS: Twenty-two subjects were recruited into a study designed to test the effects of N-3 fatty acids on liver fat content. Seventeen completed the trial that had a sequential design of 4-week placebo followed by an 8-week treatment with 9 g/d of fish oil. Liver fat was measured during placebo and treatment by magnetic resonance spectroscopy. Compliance was assessed by capsule count at the end of each study phase and measurement of fatty acid composition in plasma triglyceride and phospholipid. Plasma lipoproteins and adiponectin were also measured.
RESULTS: Treatment with fish oils reduced significantly levels of plasma triglyceride by 46% (P <.03), very low-density lipoprotein + intermediate density lipoprotein cholesterol by 21% (P <.03), total apolipoprotein B by 15% (P <.03). In contrast to the changes in plasma triglycerides, hepatic triglyceride content was not significantly reduced by fish oil treatment.
CONCLUSIONS: N-3 fatty acids at high doses lower plasma triglyceride levels, but there are no significant decreases in hepatic content of triglyceride for the group as a whole. Whereas the triglyceride lowering is uniform, the liver response is more variable.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18525453     DOI: 10.2310/JIM.0b013e318177024d

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  19 in total

Review 1.  The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease.

Authors:  Maria Del Ben; Licia Polimeni; Francesco Baratta; Daniele Pastori; Francesco Angelico
Journal:  Br J Clin Pharmacol       Date:  2016-03-04       Impact factor: 4.335

2.  Adipose tissue dysfunction in humans: a potential role for the transmembrane protein ENPP1.

Authors:  Manisha Chandalia; Himara Davila; Wentong Pan; Magdalena Szuszkiewicz; Demidmaa Tuvdendorj; Edward H Livingston; Nicola Abate
Journal:  J Clin Endocrinol Metab       Date:  2012-09-25       Impact factor: 5.958

Review 3.  Dyslipidemia in patients with nonalcoholic fatty liver disease.

Authors:  Hemant Chatrath; Raj Vuppalanchi; Naga Chalasani
Journal:  Semin Liver Dis       Date:  2012-03-13       Impact factor: 6.115

Review 4.  Efficacy of Dietary Manipulations for Depleting Intrahepatic Triglyceride Content: Implications for the Management of Non-alcoholic Fatty Liver Disease.

Authors:  Karoline Sandby; Nina Rica Wium Geiker; Maria Dalamaga; Henning Grønbæk; Faidon Magkos
Journal:  Curr Obes Rep       Date:  2021-02-13

5.  Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis.

Authors:  Srinivasan Dasarathy; Jaividhya Dasarathy; Amer Khiyami; Lisa Yerian; Carol Hawkins; Ruth Sargent; Arthur J McCullough
Journal:  J Clin Gastroenterol       Date:  2015-02       Impact factor: 3.062

Review 6.  Effect of fish oil on circulating adiponectin: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Jason H Y Wu; Leah E Cahill; Dariush Mozaffarian
Journal:  J Clin Endocrinol Metab       Date:  2013-05-23       Impact factor: 5.958

Review 7.  Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease.

Authors:  Matteo Nicola Dario Di Minno; Anna Russolillo; Roberta Lupoli; Pasquale Ambrosino; Alessandro Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2012-11-07       Impact factor: 5.742

8.  Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data.

Authors:  A N Mavrogiannaki; I N Migdalis
Journal:  Int J Endocrinol       Date:  2013-04-03       Impact factor: 3.257

9.  Exercise and Omega-3 Polyunsaturated Fatty Acid Supplementation for the Treatment of Hepatic Steatosis in Hyperphagic OLETF Rats.

Authors:  Sarah J Borengasser; R Scott Rector; Grace M Uptergrove; E Matthew Morris; James W Perfield; Frank W Booth; Kevin L Fritsche; Jamal A Ibdah; John P Thyfault
Journal:  J Nutr Metab       Date:  2011-09-12

10.  Effects of protein and omega-3 supplementation, provided during regular dialysis sessions, on nutritional and inflammatory indices in hemodialysis patients.

Authors:  Zulfitri A Mat Daud; Boniface Tubie; Judy Adams; Tracey Quainton; Robert Osia; Sharon Tubie; Deepinder Kaur; Pramod Khosla; Marina Sheyman
Journal:  Vasc Health Risk Manag       Date:  2012-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.